Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.50 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.43 |
| ▸ | TOP2A | P11388 | 1/20 | 0.43 |
| ▸ | CXCR1 | P25024 | 1/20 | 0.42 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.40 |
| ▸ | ATM | Q13315 | 2/20 | 0.40 |
| ▸ | LSS | P48449 | 1/20 | 0.40 |
| ▸ | BACE1 | P56817 | 1/20 | 0.40 |
| ▸ | PIM1 | P11309 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | ACHE | P22303 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3336783 | 0.89 | HRH3 (0.42) | HRH3HSP90AB1TOP2ACXCR1NUDT1 | |
| SCHEMBL3335084 | 0.88 | HRH3 (0.43) | HRH3HSP90AB1TOP2ACXCR1NUDT1 | |
| SCHEMBL3340124 | 0.86 | TOP2A (0.43) | HRH3HSP90AB1TOP2ANUDT1ATM | |
| SCHEMBL3337194 | 0.84 | TOP2A (0.41) | HRH3TOP2ANUDT1ATMLSS | |
| SCHEMBL5139806 | 0.81 | TOP2A (0.39) | HRH3TOP2ANUDT1ATMPIM1 | |
| SCHEMBL3335376 | 0.81 | ADORA2A (0.42) | HRH3TOP2ANUDT1ATMLSS | |
| SCHEMBL3335114 | 0.81 | TOP2A (0.46) | HRH3TOP2ANUDT1PIM1 | |
| SCHEMBL3336663 | 0.78 | BCHE (0.46) | TOP2ANUDT1ACHE | |
| SCHEMBL3340191 | 0.76 | ALOX5AP (0.41) | TOP2ANUDT1BACE1PIM1 | |
| SCHEMBL3337214 | 0.75 | ATM (0.53) | HSP90AB1ATMBACE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8673929-B2 | 4,6-di- and 2,4,6-trisubstituted quinazoline derivatives and pharmaceutical compositions useful for treating viral infections | GILEAD SCIENCES, INC. (US) | 2014-03-18 | — | — | US | claimed |
| US-20100143299-A1 | 4,6-DI- AND 2,4,6-TRISUBSTITUTED QUINAZOLINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS USEFUL FOR TREATING VIRAL INFECTIONS | GILEAD SCIENCES, INC. (US) | 2010-06-10 | — | — | US | claimed |
| WO-2008009077-A2 | 4,6-DL- AND 2,4,6-TRISUBSTITUTED QUINAZOLINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS USEFUL FOR TREATING VIRAL INFECTIONS | GILEAD SCIENCES, INC. (US) | 2008-01-24 | — | — | WO | claimed |
| US-8673929-B2 | 4,6-di- and 2,4,6-trisubstituted quinazoline derivatives and pharmaceutical compositions useful for treating viral infections | GILEAD SCIENCES, INC. (US) | 2014-03-18 | — | — | US | disclosed |
| US-20100143299-A1 | 4,6-DI- AND 2,4,6-TRISUBSTITUTED QUINAZOLINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS USEFUL FOR TREATING VIRAL INFECTIONS | GILEAD SCIENCES, INC. (US) | 2010-06-10 | — | — | US | disclosed |
| WO-2008009077-A2 | 4,6-DL- AND 2,4,6-TRISUBSTITUTED QUINAZOLINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS USEFUL FOR TREATING VIRAL INFECTIONS | GILEAD SCIENCES, INC. (US) | 2008-01-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100143299-A1 | 4,6-DI- AND 2,4,6-TRISUBSTITUTED QUINAZOLINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS USEFUL FOR TREATING VIRAL INFECTIONS | OPRD1, IFNAR1, NR4A1 | HRH3 96/4885HSP90AB1 4854/4885TOP2A 1103/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.